A re-irradiation dose of 55–60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy

por Wu, Xun, Hu, Xingsheng, Chen, Junru, He, Lang
Publicado 2021

Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial

por Shi, Yuankai, Hu, Yi, Hu, Xingsheng, Li, Xue, Lin, Lin, Han, Xiaohong
Publicado 2015

Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report

por Feng, Yu, Cao, Yufeng, Yuan, Mingming, Chen, Rongrong, Ji, Xue, Hu, Xingsheng
Publicado 2019

Parental non-hereditary teratogenic exposure factors on the occurrence of congenital heart disease in the offspring in the northeastern Sichuan, China

por Liang, Yun, Hu, Xingsheng, Li, Xiaoqin, Wen, Bing, Wang, Liang, Wang, Cheng
Publicado 2020

A predictive model of offspring congenital heart disease based on maternal risk factors during pregnancy: a hospital based case-control study in Nanchong City

por Liang, Yun, Li, Xiaoqin, Hu, Xingsheng, Wen, Bing, Wang, Liang, Wang, Cheng
Publicado 2020

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small ce...

por Xu, Ziyi, Li, Teng, Hu, Xingsheng, Hao, Xuezhi, Xing, Puyuan, Li, Junling
Publicado 2021

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study

por Feng, Yu, Huang, Liling, Zhu, Haohua, Tang, Le, Hu, Xingsheng, Shi, Yuankai
Publicado 2022

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance

por Wang, Mingzhao, Zhao, Jun, Chen, Tong, Hu, Xingsheng, Wang, Lin, Shi, Yuankai, Liu, Yutao
Publicado 2023

Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

por Hu, Xingsheng, Pu, Ke, Feng, Xuqin, Wen, Shimin, Fu, Xi, Guo, Cuihua, He, Wenwu
Publicado 2016

Is IMRT Superior or Inferior to 3DCRT in Radiotherapy for NSCLC? A Meta-Analysis

por Hu, Xingsheng, He, Wenwu, Wen, Shimin, Feng, Xuqin, Fu, Xi, Liu, Yusong, Pu, Ke
Publicado 2016

A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung...

por Hu, Xingsheng, Wang, Lin, Lin, Lin, Han, Xiaohong, Dou, Guifang, Meng, Zhiyun, Shi, Yuankai
Publicado 2016

Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations

por Zhang, Yan, Wang, Zheng, Hao, Xuezhi, Hu, Xingsheng, Wang, Hongyu, Wang, Yan, Ying, Jianming
Publicado 2017

Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis

por Ma, Di, Wang, Jing, Hao, Xuezhi, Wang, Yan, Hu, Xingsheng, Xing, Puyuan, Li, Junling
Publicado 2017

First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China

por Qi, Fei, Hu, Xingsheng, Liu, Yutao, Wang, Zhijie, Duan, Jianchun, Wang, Jie, Dong, Mei
Publicado 2019

Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China

por Hu, Xingsheng, Hu, Chunhong, Zhong, Ping, Wen, Yajing, Yang, Yong, Chen, Juan, Chen, Xiangyu
Publicado 2020

Clinical characteristics and risk factors for severity of COVID-19 outside Wuhan: a double-center retrospective cohort study of 213 cases in Hunan, China

por Hu, Xingsheng, Hu, Chunhong, Yang, Yong, Chen, Juan, Zhong, Ping, Wen, Yajing, Chen, Xiangyu
Publicado 2020

Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China

por Hu, Xingsheng, Hu, Chunhong, Jiang, Dixuan, Zuo, Qian, Li, Ya, Wang, Yang, Chen, Xiangyu
Publicado 2020

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis

por Feng, Yu, Tao, Yunxia, Chen, Haizhu, Zhou, Yu, Tang, Le, Liu, Chenwei, Hu, Xingsheng, Shi, Yuankai
Publicado 2023

Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, singl...

por Yang, Lu, Yang, Sheng, Liu, Yutao, Li, Junling, Hu, Xingsheng, Wang, Yalei, Zhang, Yan, Wang, Yan
Publicado 2018

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

por Mu, Yuxin, Hao, Xuezhi, Xing, Puyuan, Hu, Xingsheng, Wang, Yan, Li, Teng, Zhang, Jinyao, Xu, Ziyi, Li, Junling
Publicado 2020